Rivastigmine: An open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years

Martin R. Farlow, Mary L. Lilly

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'Rivastigmine: An open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years'. Together they form a unique fingerprint.

Medicine & Life Sciences